TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00327197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
Study: NCT01406678

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Coronary artery bypass surgery without remote ischemic preconditioning protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isoflurane+sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoflurane+sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study: NCT00327197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
Study: NCT01745549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle for insulin pen, 4 mm long and with a diameter of 33 gauge

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
Study: NCT01209325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT04466670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetylsalicylic acid
Description: acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin nebulized
Description: unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Study: NCT02974543

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Treatment: unimodal auditory stimulation
Description: All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Treatment: unimodal auditory stimulation
Description: All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.

Intervention type: DEVICE
Group type: OTHER
Intervention: Active Treatment: Bimodal auditory-somatosensory stimulation
Description: Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.

Intervention type: DEVICE
Group type: OTHER
Intervention: Active Treatment: Bimodal auditory-somatosensory stimulation
Description: Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.
Study: NCT03763097

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic floor ultrasound
Description: Pelvic floor ultrasound will include transperineal and introital ultrasound
Study: NCT02135913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: All subjects enrolled into the study will be prescribed standard of care Vitamin D
Study: NCT01396070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10.
Study: NCT04460001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetate
Description: intravitreal
Study: NCT01561313

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
Study: NCT01988285

Intervention type: OTHER
Intervention: Specimen Collection
Description: Blood collection, possible saliva collection, possible urine collection, and biopsy collection

Intervention type: OTHER
Intervention: Specimen Collection
Description: Blood collection, possible saliva collection, possible urine collection, and biopsy collection

Intervention type: OTHER
Intervention: Questionnaires
Description: Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use

Intervention type: OTHER
Intervention: Questionnaires
Description: Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
Study: NCT00243438

Intervention type: DEVICE
Intervention: Multilink Vision™ Stent (CE-labeled)
Description: Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
Study: NCT00916929

Intervention type: DEVICE
Group type: OTHER
Intervention: Impedance Monitoring Feature
Description: Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads

Intervention type: DEVICE
Group type: OTHER
Intervention: Impedance Monitoring Feature
Description: Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
Study: NCT02410564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy for insomnia (CBTI)
Description: SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist control condition
Description: Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
Study: NCT02053376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
Study: NCT01360736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning - Military (SAFE MIL)
Description: The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
Study: NCT01160822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Intra-articular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to canakinumab
Description: Intra-articular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to canakinumab
Description: Intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to canakinumab
Description: Intra-articular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Naproxen
Description: Tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Naproxen
Description: Tablets for oral administration
Study: NCT03037580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Sustained-release oral tablets for TID administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) for TID oral administration
Study: NCT01742286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat.
Study: NCT02400385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib 50mg/day po, 4 weeks on 2 weeks off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab 3mg/kg IV ever 2 weeks
Study: NCT04121793

Intervention type: DEVICE
Intervention: Kinesia 360 and Smartphone sensors
Description: Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
Study: NCT00870519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123-MNI-168
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123-MNI-168
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I MNI-168
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I MNI-168
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Study: NCT02052999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1%
Description: Participants received topical PAC-14028 cream 1% twice daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Participants received topical Vehicle twice daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rozex gel 0.75%
Description: Participants received topical Rozex gel 0.75% twice daily for 8 weeks
Study: NCT02665832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
Study: NCT04121585

Intervention type: DEVICE
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
Study: NCT01708902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin2.5mg/metformin1000mg
Description: linagliptin2.5mg/metformin1000mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin2.5mg/metformin1000mg
Description: linagliptin2.5mg/metformin1000mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin 5mg
Description: linagliptin 5mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500mg
Description: Metformin 500mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin2.5mg/metformin500mg
Description: linagliptin2.5mg/metformin500mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin2.5mg/metformin500mg
Description: linagliptin2.5mg/metformin500mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin 5mg
Description: linagliptin 5mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000mg
Description: Metformin 1000mg BID
Study: NCT00499590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib
Description: Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib
Description: Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
Study: NCT04541771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri DSM 17938
Description: The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
Study: NCT00530816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
Study: NCT04146636

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: e-LIFT
Description: Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and \< 15 kPa)
Study: NCT01490489

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample and doppler Ultrasound of uterine arteries
Description: * 36 ml of blood samples (serum and plasma) will be collected~* After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch
Study: NCT04413682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Supervised Exercise
Description: Structured Exercise Program under the supervision of Physical Therapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured telerehabilitation
Description: Structured Exercise Program checked and controlled through telerehabilitation
Study: NCT01812278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study: NCT02116205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTNV/PUUV DNA vaccine
Description: HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTNV/PUUV DNA vaccine
Description: HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTNV/PUUV DNA vaccine
Description: HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTNV/PUUV DNA vaccine
Description: HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System (TDS)
Description: The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System (TDS)
Description: The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System (TDS)
Description: The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System (TDS)
Description: The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
Study: NCT00757471

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brillant Blue
Description: Membrane Peeling with Brillant Blue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: Membrane Peeling with indocyanine Green
Study: NCT02816385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade cardioplegia
Description: Injection of the cardioplegia in the coronary arteries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Description: Injection of the cardioplegia in the venous system
Study: NCT04059588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2141 V-11
Description: intratumoral injection of 2141-V11
Study: NCT01079299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent, gradient, pneumatic compression device
Description: lymphedema pump provides external compression in a segmental,gradient fashion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, gradient, pneumatic compression device
Description: lymphedema pump provides external compression in a segmental,gradient fashion
Study: NCT04297527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.